INBP Sets Dec. 1 Annual Meeting; Key Director Election, Comp Votes on Tap

TL;DR

**INBP's annual meeting is a formality; insiders already control the vote, so expect board and compensation proposals to pass easily.**

AI Summary

INTEGRATED BIOPHARMA INC (INBP) is holding its 2025 Annual Meeting on December 1, 2025, to address key governance matters. Stockholders will vote on the election of Eric Friedman as a Class III director for a three-year term expiring in 2028, provide a non-binding advisory vote on executive compensation, and another non-binding advisory vote on the frequency of future executive compensation votes. Additionally, shareholders will ratify the appointment of CBIZ CPAs P.C. as the independent auditor for the fiscal year ending June 30, 2026. As of the October 17, 2025 Record Date, 31,059,610 shares of Common Stock were outstanding and entitled to vote. The Board of Directors unanimously recommends a 'FOR' vote on all proposals. Notably, William H. Milmoe beneficially owns 42.5% of the common stock, and Dean DeSantis owns 41.2%, indicating significant insider control.

Why It Matters

This DEF 14A filing outlines critical governance decisions for INTEGRATED BIOPHARMA INC, directly impacting investor confidence and corporate oversight. The election of a Class III director and advisory votes on executive compensation and its frequency are crucial for shaping future leadership and compensation practices, which can influence long-term shareholder value. The ratification of CBIZ CPAs P.C. as auditor ensures continued financial transparency. With significant insider ownership, particularly William H. Milmoe at 42.5% and Dean DeSantis at 41.2%, the outcome of these votes is largely predetermined, potentially limiting the influence of minority shareholders and raising questions about independent oversight compared to competitors.

Risk Assessment

Risk Level: low — The risk level is low because the Board of Directors unanimously recommends 'FOR' all proposals, and significant insider ownership (William H. Milmoe at 42.5% and Dean DeSantis at 41.2%) makes it highly probable these proposals will pass, reducing uncertainty for investors regarding these specific agenda items.

Analyst Insight

Investors should review the executive compensation proposals to understand potential future costs, but given the high insider ownership, direct opposition is unlikely to succeed. Focus on the company's operational performance and future strategic announcements rather than the outcome of these governance votes.

Key Numbers

• 31,059,610 — Shares of Common Stock outstanding (Entitled to vote as of Record Date October 17, 2025)
• 42.5% — Beneficial ownership by William H. Milmoe (Significant insider control over voting matters)
• 41.2% — Beneficial ownership by Dean DeSantis (Significant insider control over voting matters)
• 67.4% — Beneficial ownership by Directors and executive officers as a group (Collective insider control over voting matters)
• December 1, 2025 — Date of Annual Meeting (Key date for stockholder decisions)
• October 17, 2025 — Record Date (Date for determining eligible voters)
• 3 years — Term for Class III director (Duration of elected director's service)
• 9:00 a.m. — Meeting start time (Local time for the Annual Meeting)
• June 30, 2026 — Fiscal year end (Period for which independent auditor is appointed)
• $.002 — Par value per share (Par value of Common Stock)

Key Players & Entities

• INTEGRATED BIOPHARMA INC (company) — Registrant for DEF 14A filing
• Christina Kay (person) — Co-Chief Executive Officer and Class II Director
• Riva Sheppard (person) — Co-Chief Executive Officer and Class I Director
• Eric Friedman (person) — Class III Director nominee for election
• CBIZ CPAs P.C. (company) — Proposed independent auditor for fiscal year ending June 30, 2026
• William H. Milmoe (person) — Class II Director and 42.5% beneficial owner of Common Stock
• Damon DeSantis (person) — Class I Director and 0.5% beneficial owner of Common Stock
• Dean DeSantis (person) — 41.2% beneficial owner of Common Stock
• Robert Canarick (person) — Class II Director and 2.2% beneficial owner of Common Stock
• Dina L. Masi (person) — Secretary and 2.9% beneficial owner of Common Stock

FAQ

Industry Context

Integrated BioPharma Inc. operates within the biotechnology and pharmaceutical sector, a highly competitive and research-intensive industry. Companies in this space focus on drug discovery, development, and commercialization, often requiring significant capital investment and navigating complex regulatory pathways. Key trends include advancements in personalized medicine, biologics, and the increasing demand for innovative treatments for various diseases.

Regulatory Implications

As a biopharmaceutical company, Integrated BioPharma Inc. is subject to stringent regulations from bodies like the FDA concerning drug development, clinical trials, manufacturing, and marketing. Compliance with these regulations is critical to avoid delays, fines, or product recalls. The company's operations and financial performance are directly impacted by the success or failure of regulatory approval processes.

What Investors Should Do

1. Vote FOR the election of Eric Friedman as a Class III director.
2. Vote FOR the non-binding advisory proposal on executive compensation.
3. Vote FOR the non-binding advisory proposal on the frequency of executive compensation votes.
4. Vote FOR the ratification of CBIZ CPAs P.C. as the independent auditor.

Key Dates

• 2025-12-01: Annual Meeting of Stockholders — Key date for voting on director elections, executive compensation, auditor ratification, and meeting frequency.
• 2025-10-17: Record Date — Determined the stockholders eligible to vote at the Annual Meeting.
• 2026-06-30: Fiscal Year End — The period for which the independent auditor, CBIZ CPAs P.C., is appointed.

Glossary

DEF 14A

A proxy statement filing required by the U.S. Securities and Exchange Commission (SEC) for publicly traded companies to solicit shareholder votes. (This document contains the information presented, detailing the agenda and proposals for the company's annual meeting.)

Beneficial Ownership

The actual right to use or dispose of a security, even if it is not registered in the owner's name. This can include shares owned by family members or entities controlled by the individual. (Crucial for understanding control and influence within the company, as highlighted by the significant holdings of William H. Milmoe and Dean DeSantis.)

Class III Director

A director elected to serve a specific term, typically three years, as part of a classified board structure where directors are divided into groups. (Eric Friedman is proposed for election as a Class III director for a three-year term expiring in 2028.)

Non-binding Advisory Vote

A shareholder vote on a proposal that is not legally binding on the company's board of directors, often referred to as a 'say-on-pay' vote. (Shareholders will vote on executive compensation and the frequency of such votes, providing advisory input to the board.)

Ratification

The act of approving or confirming a previous action or decision, in this case, the appointment of an independent auditor. (Shareholders are asked to ratify the board's appointment of CBIZ CPAs P.C. as the independent auditor.)

Year-Over-Year Comparison

This analysis is based on a single filing (DEF 14A) and does not contain comparative financial data from a previous filing. Therefore, a comparison of key metrics such as revenue growth, margin changes, or the emergence of new risks cannot be provided.

Filing Documents

• inbp20251008_def14a.htm (DEF 14A) — 534KB
• ibp_logo.jpg (GRAPHIC) — 12KB
• 0001437749-25-031864.txt ( ) — 945KB
• inbp-20250630.xsd (EX-101.SCH) — 4KB
• inbp-20250630_def.xml (EX-101.DEF) — 2KB
• inbp-20250630_lab.xml (EX-101.LAB) — 2KB
• inbp-20250630_pre.xml (EX-101.PRE) — 1KB
• inbp20251008_def14a_htm.xml (XML) — 31KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information regarding the number of shares of Common Stock of Integrated BioPharma, Inc. beneficially owned on October 17, 2025 by: each person who is known by the Company to beneficially own five percent (5%) or more of the Common Stock of the Company; each of the directors and executive officers of the Company; and all of the Company's directors and executive officers, as a group. Number of Shares Percent of Shares Name of Beneficial Owne r (1) Beneficially Owned ( 2 ) Beneficially Owned ( 3 ) William H. Milmoe 13,355,558 (4) 42.5% Dean DeSantis 12,784,391 (5) 41.2% Carl DeSantis Revocable Trust 12,766,982 (6) 41.1% Deborah DeSantis 12,766,982 (7) 41.1% Riva Sheppard 5,556,346 (8) 17.5% Christina Kay 5,540,646 (9) 17.5% Heidi Kay 5,019,161 (10) 16.2% Estate of E Gerald Kay 3,393,815 10.9% Dina L Masi 903,837 (12) 2.9% Robert Canarick 696,733 (13) 2.2% Eric Friedman 262,500 (14) 0.8% Damon DeSantis 162,500 (15) 0.5% Directors and executive officers as a group (7 persons) 23,114,334 (16) 67.4% 5 (1) The address of each of the persons listed is c/o Integrated BioPharma Inc., 225 Long Avenue, Hillside, New Jersey 07205. (2) Unless otherwise indicated, includes shares owned by a spouse, minor children, by relatives sharing the same home, and entities owned or controlled by the named person. Also includes shares if the named person has the right to acquire such shares within 60 days after October 17, 2025, by the exercise of warrant, stock option or other right. Unless otherwise noted, shares are owned of record and beneficially by the named person. (3) Based upon 31,059,610 shares of Common Stock outstanding on October 17, 2025. (4) Includes (i) 2,242,809 shares owned by Carl DeSantis Revocable Trust (the "CDC Trust") of which Mr. Milmoe is one of the three co-trustees; (ii)

View Full Filing

View this DEF 14A filing on SEC EDGAR